Prellis Biologics›Prellis Biologics› offers EXIS

EXIS is the antibody-discovery platform developed by Prellis Biologics, pairing machine-learning design with the company's bioprinted human lymph node organoids to recreate human immune responses in the laboratory. The system screens antibodies against a chosen target using genetic material drawn from multiple donors, which broadens epitope coverage across therapeutic targets.

By retaining elements of natural in-vivo antibody generation rather than relying solely on synthetic display libraries, EXIS is positioned to help break immune tolerance to human antigens. Prellis uses the platform to surface antibody candidates with a low immunogenicity profile for its internal pipeline and for partnered drug programs.